Hambro Perks

We support our businesses with our time, energy, and experience. Healthcare Services$1-10M EBITDA 20%+ YoY growth Teams who deliver quality outcomes, reduce costs & have big visions Multi-site services including de novo and acquisition growth Potential to expand continuity of care with ancillary services B2B Software$2-10M ARR 40%+ YoY growth Momentum and vision Strong gross & net revenue retention Industry expertise & team chemistry Here’s How We Do It We meet teams and businesses where they are, and imagine a bigger and brighter future by building the right systems, processes, teams and culture. And all of that starts with the right experience, the right support, and the right relationship The Right ExperiencePartners are former executives with a combined 125+ years of experience Learn from our personal operating experience and experience with our portfolio companies We stick to what we know: technology and healthcare 60+ investments, 25+ successful exits and approaching $1B AUM The Right SupportFinancial runway so you can stay focused on your business, not your next fundraise Recruit the right people from board level to senior leadership and throughout the organization Perfect your expansion strategy with the support of our industry leading service partners Join the Fulcrum network of executives at our annual retreat and beyond The Right RelationshipThe right balance of input and autonomy Engaged partners acting as a sounding board Operators that have been in tough situations and don’t overreact and overcorrect when challenges occur Professionals who will help you imagine greater goals and help you achieve them throughout our investment and after

Impact Investing is more important than ever before. We aim to back the most innovative ideas combining impact and ground-breaking technologies. By leveraging knowledge and ensuring access to a growing network of like-minded people and organizations, we provide the best support we can to founders, especially in the early stages of their companies. We are an international team combining investment expertise and operational excellence. As a team, we have the strong belief that it needs an outstanding impact ecosystem consisting of founders, investors, governments, and other organizations to be able to sustainably meet the greatest challenges of our time. Our Investment Focus We know that beginnings can be hard. Especially when you are on a mission to change the world for the better. We invest in superior technologies provided by passionate teams that contribute to saving our planet while building scalable business models. About Us Established in 1999 in Japan, the SBI Group has formed the world’s first and leading internet-based financial conglomerate providing financial services in a broad range of fields. The SBI Group’s business fields include securities, banking and insurance (Financial Service Business), investing in and incubating start-ups through various venture capital vehicles (Asset Management Business), and undertaking the R&D and manufacturing of pharmaceuticals and health foods (Biotechnology Healthcare & Medical Informatics Business). By placing these business segments as the core of its operations, the SBI Group is taking on the challenge of realizing sustainable growth as a Strategic Business Innovator. Being one of the largest Japanese private equity firms with more than USD 4.8 billion AUM and more than 9,000 employees worldwide, the SBI Group has invested in more than 1,500 companies globally and is one of the world's largest investors in the FinTech sector. This broad platform is leveraged to further drive the value of SBI’s investments. In order to support the evolvement "from Japan’s SBI to the World’s SBI," the group established its first Western European representative office in Berlin in March 2019. In recent years, it has increased its investments in European start-ups, especially in start-ups based in Berlin.

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

Fåhraeus Startup and Growth Fund was started in 2021 by Christer Fåhraeus and Emanuel Eriksson. It is a Venture Capital fund focusing on investing early in companies in life science and tech. The goal of the investments is to take the companies up for sale or listing on the stock exchange a few years after the investment. Christer and Emanuel, together with Linus Wiebe, manage the fund. History of the fund In recent years, Christer Fåhraeus and Emanuel Eriksson have worked together with investments in small listed companies and unlisted life science and tech companies for Fårö Capital. Fårö Capital is a Family Office fund where Christer has been CEO and Emanuel Investment Manager. During the years at Fårö Capital, they decided to raise a fund for investments in companies in the same industry with excellent growth potential. Sustainability Fåhraeus Startup & Growth has integrated sustainability risks into the investment decision process at all stages of the investment life cycle. Sustainability risks include environmental, social or governance-related events or circumstances that may have a significant adverse effect on the value of the investment. The risks are initially assessed together with other types of risks as part of the due diligence work before the investment takes place. The various factors are prioritized depending on how important they are for the business, the stakeholders and the expected effect on the investment. A conclusion that there are significant sustainability risks that will not be manageable or limited results in a decision not to invest. Fåhraeus Startup & Growth does not consider the main negative consequences of investment decisions for sustainability factors because, given the fund’s size and investment strategy, it is not possible to carry out reliable due diligence from a cost-benefit perspective. However, the fund continues to evaluate and consider its obligations regarding the investments’ main negative consequences for sustainability factors. Decisions and publications can be reviewed once the technical standards have been adopted and when data and tools for measuring the significant negative consequences regarding unlisted life science and technology companies have been developed and become more efficient. Before making an investment decision, the long-term effects of the investment are taken into account, and the fund avoids taking short-term risks to achieve a profit.

We are dedicated team of experienced investors who help to enable groundbreaking work by investing in and fostering companies and technologies that advance the future of health. Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care Established by UNC REX Healthcare in 2012 as part of its commitment to innovation Partners with emerging companies throughout North Carolina and the U.S. Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network

First founded as a venture capital firm in 1999, IMM Investment has since become one of leading multi-asset alternative investment firms in Asia with $6.4 billion* of assets under management across three business segments (venture capital, growth equity and infrastructure) We continue to create significant value for our portfolio companies. Established in September 1999, IMM Investment Corp. is the leading alternative investment firm in Korea, focusing on Venture Capital, Mezzanine and Infrastructure. With longstanding trust of institutional investors, partners and investment professionals continue to create significant values for Portfolio companies, which consist of Information Technology, Healthcare/Biotech and Manufacturing. The Leading Investment Firm in Korea IMM Investment today is a leading firm in Korean alternative investment market. However, the position as a top player in the Korean capital market was not achieved in one day. IMM Investment has built up its track record with the strong management team based on partnership, working to increase the value of portfolio companies and distribute returns to LP investors. 1999~2006 _Growth Stage Korean VC industry emerged when ‘Special Law to Promote Venture Capital Companies' was enacted in 1997. IMM Investment was established in September 1999. In 2000, the company merged with GEO Investment and set foundation for future growth. In the initial years, IMM Investment focused on IT and Culture/Contents industry and Corporate Restructuring Company (CRC). Through outstanding performance from VC and CRC, IMM Investment built successful track records, and asset under management reached KRW 207bn by December 2006. 2007~2009 _Transition After enactment of the Financial Investment Services and Capital Markets Act (formerly indirect Investment Asset Management Business Act) in 2004, CRC was gradually replaced with PEF. In the end of 2006, IMM Investment spun-off Buyout business to IMM PE and, in 2008, spun-off Culture/Contents focus to Stonebridge Capital. During this time, some of the company’s successful investments include Celltrion(Biosimilar), Novelis Korea(Manufacturing, Flat-rolled aluminum products). 2010~Present _Emergence as a leading investment firm in Korea Based on the successful track record, IMM Investment raised several VC and PEF funds since 2010. Company currently manages total of 25 VC funds (AUM KRW 1,300bn) and 23 PEF (AUM KRW 6,400bn). In addition to VC, IMM Investment also made several investments in medium-to-large sized enterprises or infrastructures, notably Hanjin Newport, PSA Hyundai Pusan Newport Terminal, Hyundai LNG Shipping, and Incheon Total Energy Company. IMM Investment is currently actively pursuing both domestic and overseas investment opportunities.